Treatment

Fulvestrant 250 mg solution for injection in pre-filled syringe clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
"DEMETER": Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients: a multicenter phase II trial
This study is testing a new drug, milademetan, alongside an existing treatment, fulvestrant, for a specific type of advanced breast cancer. Researchers want to see if this combination helps shrink tumours or stop their growth in patients with certain genetic markers.
For: GATA3-mutant · ER-positive · HER2-negative advanced or metastatic breast cancer
France